Metabolomics Workbench : NIH Data Repository

Clustering data with hclust algorithm for Rat Colon Study effect of Effect of fish oil on azoxymethane (AOM) (Study ST000778)

C18 NEGATIVE ION MODE (Analysis AN001230)

Metabolite	Structure	F1	F2	F3	F4	F5	F6
lysoPE 25:0; [M-H]-@5.66	ME215655	0.26	0.62	1.12	0.49	4.32	0.34
lysoPE 22:0; [M-H]-@4.31	ME215650	0.25	0.22	2.25	0.20	4.19	0.37
lysoPE 26:0; [M-H]-@6.03	ME215656	0.12	0.15	1.73	0.18	5.13	0.31
lysoPE 18:0; [M-H]-@2.38	ME215644	0.33	0.30	2.14	0.39	3.33	0.68
lysoPE 19:0; [M-H]-@2.83	ME215646	0.31	0.42	1.82	0.41	3.44	0.69
PC 40:8; [M-Ac-H]-@5.80	ME215525	0.55	0.66	1.50	0.51	2.99	0.62
PG 44:11; [M-H]-@4.76	ME215605	0.37	0.60	1.46	0.30	2.92	1.13
PG 42:11; [M-H]-@4.22	ME215600	0.09	0.82	0.97	0.32	3.52	1.10
PG 44:12; [M-H]-@4.44	ME215606	0.10	1.01	0.30	0.12	3.63	1.49
PA 38:5; [M-H]-@5.44	ME215475	0.60	1.41	0.44	0.23	2.07	1.42
plasmenyl-PE 36:5; [M-H]-@6.29	ME215665	0.24	1.58	0.21	0.13	2.44	1.62
PC 34:5; [M-Ac-H]-@5.16	ME215498	0.08	2.09	0.07	0.32	1.97	1.49
PC 36:5; [M-Ac-H]-@5.76	ME215508	0.36	1.82	0.46	0.33	1.44	1.55
plasmenyl-PE 42:6; [M-H]-@7.77	ME215678	0.35	1.99	0.24	0.29	1.27	1.70
lysoPE 20:5; [M-H]-@1.01	ME215649	0.22	1.87	0.25	0.67	1.53	1.38
PI 38:6; [M-H]-@5.11	ME215619	0.41	1.61	0.61	0.66	1.59	1.18
CL 74:9; [M-2H](2-)@5.95	ME215446	0.16	2.13	0.13	0.16	1.04	2.11
PS 41:6; [M-H]-@6.06	ME215641	0.81	1.83	0.16	0.52	0.73	1.59
PS 40:5; [M-H]-@6.06	ME215639	0.57	1.93	0.23	0.42	0.56	1.89
PS 40:6; [M-H]-@5.86	ME215640	0.57	2.08	0.30	0.44	0.49	1.71
PE 36:6; [M-H]-@5.43	ME215550	0.36	2.65	0.61	0.28	0.48	1.32
PE 38:6; [M-H]-@6.13	ME215558	0.68	2.28	0.46	0.43	0.42	1.35
PE 42:4; [M-H]-@7.99	ME215573	1.85	0.68	1.01	0.91	0.48	0.91
CL 78:11; [M-2H](2-)@9.20	ME215452	1.94	0.43	0.73	1.45	0.39	0.77
PE 40:4; [M-H]-@7.39	ME215565	1.97	0.48	1.20	1.55	0.19	0.41
PS 40:4; [M-H]-@6.36	ME215638	2.06	0.45	1.24	1.47	0.24	0.37
PG 33:1; [M-H]-@5.48	ME215581	0.66	1.29	1.41	0.36	1.19	1.29
PI 40:6; [M-H]-@5.77	ME215623	0.18	1.46	1.04	0.47	1.61	1.46
PC 43:4; [M-Ac-H]-@8.39	ME215531	0.63	0.80	1.00	0.74	1.82	1.29
CL 70:4; [M-2H](2-)@9.42	ME215434	0.79	0.60	1.07	0.76	1.93	1.17
PG 32:0; [M-H]-@5.68	ME215578	0.71	0.53	1.10	0.72	1.94	1.35
PC 33:1; [M-Ac-H]-@6.46	ME215492	0.77	0.79	1.21	0.51	2.13	1.04
PC 35:1; [M-Ac-H]-@7.05	ME215499	0.68	0.97	0.97	0.66	2.09	0.98
PI 40:5; [M-H]-@5.94	ME215622	0.82	1.08	0.82	0.86	1.77	0.86
PC 31:2; [M-Ac-H]-@5.30	ME215486	0.71	0.75	1.41	1.00	1.50	0.93
plasmenyl-PE 36:0; [M-H]-@8.18	ME215661	0.70	0.53	1.36	1.19	1.36	1.10
FFA(18:2)	ME215458	0.74	0.62	1.11	1.09	1.62	1.06
FFA(18:1)	ME215457	0.83	0.57	1.22	1.08	1.53	1.02
FFA(16:0)	ME215455	0.83	0.65	1.13	1.08	1.40	1.09
FFA(18:0)	ME215456	0.84	0.68	1.12	1.08	1.46	1.02
PC 32:2; [M-Ac-H]-@5.65	ME215489	0.79	1.12	1.29	0.71	1.34	0.96
PC 30:1; [M-Ac-H]-@5.45	ME215482	0.98	1.05	1.36	0.70	1.39	0.77
PC 34:1; [M-Ac-H]-@6.69	ME215494	0.91	0.97	1.23	0.75	1.35	0.98
PC 36:3; [M-Ac-H]-@6.45	ME215506	1.01	0.93	1.31	0.75	1.30	0.90
PC 32:0; [M-Ac-H]-@6.60	ME215487	0.85	0.82	1.30	0.94	1.33	0.97
PC 40:2; [M-Ac-H]-@8.07	ME215519	0.93	0.80	1.22	0.89	1.42	0.95
PE 36:0; [M-H]-@7.87	ME215546	0.99	0.75	1.16	0.87	1.53	0.94
PC 33:2; [M-Ac-H]-@5.99	ME215493	0.80	0.84	1.33	0.70	1.50	1.10
CL 70:5; [M-2H](2-)@9.24	ME215436	0.89	0.80	1.28	0.73	1.50	1.07
plasmenyl-PE 38:1; [M-H]-@8.25	ME215666	0.88	0.87	1.21	0.74	1.51	1.03
PC 32:1; [M-Ac-H]-@6.10	ME215488	0.92	0.95	1.28	0.67	1.51	0.94
PI 36:2; [M-H]-@5.84	ME215613	0.91	0.98	1.30	0.66	1.54	0.89
PC 38:1; [M-Ac-H]-@7.95	ME215512	0.82	0.98	1.16	0.81	1.49	0.96
PC 40:1; [M-Ac-H]-@8.53	ME215518	0.78	0.90	1.32	0.82	1.54	0.92
PC 40:7; [M-Ac-H]-@6.28	ME215524	0.69	1.13	1.28	0.60	1.26	1.22
PC 34:3; [M-Ac-H]-@5.80	ME215496	0.64	1.03	1.47	0.80	1.25	1.05
PC 42:3; [M-Ac-H]-@8.19	ME215529	0.67	0.93	1.25	0.84	1.31	1.19
PC 42:2; [M-Ac-H]-@8.62	ME215528	0.60	0.90	1.44	0.66	1.61	1.14
PC 42:1; [M-Ac-H]-@9.04	ME215527	0.55	1.05	1.28	0.75	1.74	0.98
PI 34:2; [M-H]-@5.22	ME215611	0.66	1.00	1.35	0.59	1.75	1.02
PG 34:2; [M-H]-@5.40	ME215583	0.61	1.22	1.13	0.70	1.64	0.97
PI 38:5; [M-H]-@5.39	ME215618	0.71	1.31	0.91	0.56	1.60	1.08
PI 36:1; [M-H]-@6.27	ME215612	0.87	1.01	1.14	0.50	1.76	1.02
plasmenyl-PE 33:1; [M-H]-@6.90	ME215658	0.85	0.93	0.93	0.57	1.78	1.18
PC 41:1; [M-Ac-H]-@8.79	ME215526	0.77	0.68	1.16	0.80	1.59	1.25
PC 33:0; [M-Ac-H]-@6.87	ME215491	0.72	1.06	0.99	0.64	1.61	1.18
PC 34:2; [M-Ac-H]-@6.27	ME215495	0.70	1.08	1.03	0.72	1.52	1.13
plasmenyl-PE 34:0; [M-H]-@7.23	ME215659	0.73	0.89	1.13	0.79	1.57	1.12
plasmenyl-PE 34:1; [M-H]-@7.14	ME215660	0.69	0.96	1.08	0.72	1.48	1.26
Arachidonic acid	ME215429	0.65	0.37	1.71	1.18	1.84	0.77
FFA(20:1)	ME215460	0.51	0.35	1.69	1.05	2.38	0.71
FFA(22:1)	ME215463	0.55	0.40	1.63	1.12	2.21	0.70
FFA(24:0)	ME215466	0.56	0.42	1.04	1.54	1.95	0.82
FFA(22:0)	ME215462	0.56	0.48	1.14	1.27	1.94	0.97
FFA(20:0)	ME215459	0.63	0.49	1.32	1.15	1.97	0.86
FFA(24:1)	ME215467	0.58	0.44	1.39	1.01	2.11	0.97
PI 38:3; [M-H]-@6.04	ME215616	0.54	0.76	1.64	0.50	2.47	0.78
PG 40:7; [M-H]-@5.04	ME215597	0.68	0.53	1.86	0.62	2.25	0.76
PG 40:8; [M-H]-@4.60	ME215598	0.75	0.49	2.10	0.56	2.13	0.71
PG 42:10; [M-H]-@4.56	ME215599	0.77	0.45	1.52	0.69	2.12	0.99
PC 29:0; [M-Ac-H]-@5.64	ME215480	1.11	0.69	1.49	0.63	1.57	0.86
PC 44:4; [M-Ac-H]-@8.64	ME215532	0.97	0.74	1.67	0.61	1.69	0.77
PC 44:5; [M-Ac-H]-@8.11	ME215533	0.91	0.63	1.61	0.82	1.68	0.78
lysoPE 20:3; [M-H]-@1.60	ME215648	0.88	0.68	1.82	0.54	2.02	0.69
PI 36:3; [M-H]-@5.45	ME215614	0.84	0.74	1.72	0.64	2.05	0.60
PC 31:1; [M-Ac-H]-@5.79	ME215485	0.75	0.62	1.71	0.85	1.85	0.75
PC 30:0; [M-Ac-H]-@5.98	ME215481	0.73	0.77	1.60	0.75	1.89	0.76
PC 31:0; [M-Ac-H]-@6.33	ME215484	0.84	0.84	1.56	0.60	1.88	0.75
lysoPE 22:4; [M-H]-@1.79	ME215653	1.61	0.37	2.01	1.06	0.73	0.46
PS 42:5; [M-H]-@6.58	ME215642	1.73	0.41	1.98	0.95	0.64	0.50
PC 35:3; [M-Ac-H]-@6.20	ME215501	0.55	0.84	1.91	0.89	1.06	1.07
PC 26:0; [M-Ac-H]-@4.48	ME215477	0.97	0.65	1.92	0.98	0.83	0.90
CL 68:2; [M-2H](2-)@9.56	ME215432	0.82	0.71	1.87	1.07	1.09	0.76
PC 42:5; [M-Ac-H]-@7.55	ME215530	0.92	0.86	1.92	0.93	1.03	0.65
PC 40:3; [M-Ac-H]-@7.64	ME215520	1.39	0.78	1.23	0.74	1.31	0.73
CL 72:6; [M-2H](2-)@9.30	ME215439	1.02	0.78	1.15	1.10	1.19	0.86
CL 74:8; [M-2H](2-)@9.20	ME215445	1.10	0.78	1.18	1.16	1.03	0.82
PG 38:2; [M-H]-@6.11	ME215589	0.93	0.79	1.26	1.28	0.90	0.89
PI 39:4; [M-H]-@6.09	ME215620	0.87	0.76	1.33	1.10	1.10	0.99
PI 40:4; [M-H]-@6.28	ME215621	0.86	0.75	1.30	1.23	1.17	0.86
PG 36:3; [M-H]-@5.38	ME215587	1.07	0.88	1.43	1.12	0.75	0.81
CL 72:5; [M-2H](2-)@9.48	ME215438	1.16	0.55	1.35	1.05	1.04	0.97
PC 30:2; [M-Ac-H]-@4.92	ME215483	1.25	0.79	1.23	0.97	0.86	0.94
PC 38:3; [M-Ac-H]-@7.16	ME215514	1.21	0.72	1.45	0.91	1.03	0.84
PI 38:4; [M-H]-@5.83	ME215617	1.10	0.85	1.43	0.96	0.96	0.83
plasmenyl-PE 36:4; [M-H]-@6.65	ME215664	1.19	0.84	1.31	0.93	0.97	0.85
PC 32:4; [M-Ac-H]-@4.88	ME215490	1.09	1.05	1.77	0.66	0.97	0.71
PC 34:4; [M-Ac-H]-@5.61	ME215497	1.33	1.02	1.53	0.73	0.88	0.64
PC 28:0; [M-Ac-H]-@5.28	ME215479	1.15	0.95	1.59	0.72	1.18	0.67
PE 30:0; [M-H]-@6.09	ME215534	1.05	0.75	1.55	0.90	1.20	0.79
PC 35:4; [M-Ac-H]-@5.95	ME215502	0.99	0.81	1.78	0.86	1.23	0.66
PI 36:4; [M-H]-@5.22	ME215615	1.05	0.80	1.68	0.89	1.15	0.71
PC 36:0; [M-Ac-H]-@7.89	ME215503	0.87	0.90	1.60	0.90	1.01	0.92
PC 38:2; [M-Ac-H]-@7.48	ME215513	0.90	0.96	1.54	0.79	1.27	0.80
PG 36:4; [M-H]-@5.24	ME215588	1.04	1.07	1.39	0.70	1.06	0.90
plasmenyl-PE 40:2; [M-H]-@8.30	ME215671	0.94	0.98	1.55	0.70	1.10	0.95
PG 36:1; [M-H]-@6.33	ME215585	1.16	0.79	1.45	0.87	0.50	1.22
PE 43:4; [M-H]-@8.33	ME215575	1.53	0.98	1.63	0.82	0.37	0.66
CL 72:4; [M-2H](2-)@9.62	ME215437	1.15	0.38	1.42	1.42	1.01	0.76
CL 74:6; [M-2H](2-)@9.53	ME215443	1.41	0.37	1.35	1.24	0.96	0.77
PG 38:3; [M-H]-@6.06	ME215590	1.18	0.62	1.18	1.58	0.63	0.74
CL 76:9; [M-2H](2-)@9.26	ME215450	1.30	0.50	1.51	1.44	0.45	0.78
PE 40:3; [M-H]-@7.63	ME215564	1.52	0.69	1.25	1.44	0.35	0.62
PC 40:4; [M-Ac-H]-@7.36	ME215521	1.60	0.63	1.65	1.29	0.47	0.41
plasmenyl-PE 40:4; [M-H]-@7.66	ME215673	1.61	0.61	1.39	1.19	0.55	0.62
plasmenyl-PE 40:3; [M-H]-@7.96	ME215672	1.42	0.71	1.44	1.09	0.73	0.67
PC 38:4; [M-Ac-H]-@6.80	ME215515	1.49	0.71	1.30	1.16	0.56	0.73
PC 36:4; [M-Ac-H]-@6.15	ME215507	1.45	0.81	1.30	1.03	0.66	0.74
plasmenyl-PE 38:4; [M-H]-@7.24	ME215668	1.39	0.79	1.26	1.11	0.68	0.76
plasmenyl-PE 38:3; [M-H]-@7.52	ME215667	1.14	0.68	1.74	1.00	0.80	0.81
plasmenyl-PE 42:4; [M-H]-@8.13	ME215676	1.35	0.69	1.71	0.94	0.80	0.68
PC 37:4; [M-Ac-H]-@6.59	ME215510	1.24	0.71	1.68	1.22	0.72	0.57
PG 40:4; [M-H]-@6.06	ME215594	1.26	0.75	1.70	1.27	0.40	0.66
CL 78:12; [M-2H](2-)@9.11	ME215453	1.32	0.84	0.75	1.75	0.48	0.61
PE 42:3; [M-H]-@8.10	ME215572	1.05	0.93	0.78	1.57	0.34	1.04
PS 36:4; [M-H]-@5.29	ME215628	1.24	0.93	0.76	1.55	0.45	0.82
CL 66:3; [M-2H](2-)@5.70	ME215430	0.71	0.90	0.82	1.73	0.61	1.04
PE 32:2; [M-H]-@5.71	ME215538	0.73	0.97	0.61	1.98	0.43	0.96
PE 32:1; [M-H]-@6.22	ME215537	0.81	1.01	0.88	1.37	0.80	1.01
PE 33:2; [M-H]-@6.07	ME215539	0.86	1.08	0.58	1.64	0.72	0.90
PE 31:0; [M-H]-@6.39	ME215535	1.36	0.52	0.75	0.68	1.03	1.58
PC 35:2; [M-Ac-H]-@6.59	ME215500	1.11	0.88	0.59	0.68	1.36	1.36
PA 36:2; [M-H]-@5.84	ME215472	1.06	0.97	0.70	0.83	1.02	1.32
PA 36:1; [M-H]-@6.26	ME215471	1.29	0.95	0.68	0.86	0.99	1.12
PA 38:2; [M-H]-@6.39	ME215473	1.21	0.93	0.76	0.73	0.99	1.30
PG 32:1; [M-H]-@5.15	ME215579	1.26	0.97	0.65	0.73	1.07	1.23
PE 32:0; [M-H]-@6.73	ME215536	0.90	1.05	1.11	0.96	1.06	0.97
PC 40:5; [M-Ac-H]-@6.98	ME215522	1.00	1.09	1.23	0.77	1.01	0.98
plasmenyl-PE 42:5; [M-H]-@7.88	ME215677	1.15	0.99	1.17	0.75	1.06	0.96
PC 36:2; [M-Ac-H]-@6.87	ME215505	0.80	1.07	1.12	0.71	1.31	1.13
CL 72:7; [M-2H](2-)@9.11	ME215440	0.88	1.03	0.96	0.85	1.27	1.08
PC 36:1; [M-Ac-H]-@7.35	ME215504	0.93	1.00	1.05	0.85	1.21	1.05
lysoPE 22:5; [M-H]-@1.67	ME215654	0.88	0.99	0.75	0.82	1.27	1.29
plasmenyl-PE 36:1; [M-H]-@7.71	ME215662	0.78	0.96	1.01	0.79	1.14	1.37
PE 42:1; [M-H]-@8.92	ME215570	0.78	1.32	1.17	0.70	0.91	1.14
PE 37:1; [M-H]-@7.66	ME215551	0.84	1.08	0.82	0.90	0.81	1.43
plasmenyl-PE 36:2; [M-H]-@7.30	ME215663	0.80	1.15	0.86	0.89	0.99	1.26
PG 33:0; [M-H]-@6.01	ME215580	0.74	1.16	1.00	0.80	0.96	1.32
PS 37:1; [M-H]-@6.63	ME215629	0.89	1.12	0.99	0.77	0.95	1.25
PS 34:1; [M-H]-@5.78	ME215624	0.86	1.38	0.87	0.72	0.92	1.17
plasmenyl-PE 40:5; [M-H]-@7.55	ME215674	0.90	1.29	0.79	0.70	1.08	1.20
PS 40:1; [M-H]-@7.50	ME215636	0.91	1.23	0.89	0.81	1.09	1.07
PC 38:5; [M-Ac-H]-@6.44	ME215516	0.99	1.18	1.05	0.63	1.11	1.09
plasmenyl-PE 38:5; [M-H]-@6.77	ME215669	1.02	1.11	0.94	0.81	0.96	1.13
PS 38:4; [M-H]-@5.92	ME215633	1.41	0.99	0.98	1.09	0.40	0.93
PE 42:5; [M-H]-@7.70	ME215574	1.17	0.94	1.06	1.24	0.30	1.08
PE 40:2; [M-H]-@8.00	ME215563	1.19	0.88	1.05	1.30	0.42	0.98
PE 44:5; [M-H]-@8.10	ME215577	1.23	0.98	0.94	1.29	0.38	0.94
PA 38:4; [M-H]-@5.80	ME215474	1.53	0.75	0.81	1.08	0.67	0.98
CL 76:10; [M-2H](2-)@9.11	ME215447	1.23	0.85	0.82	1.30	0.66	0.96
PA 40:5; [M-H]-@6.07	ME215476	1.29	0.87	1.04	1.13	0.66	0.92
CL 78:1; [M-2H](2-)@8.00	ME215451	1.27	0.98	0.87	1.01	0.64	1.06
PS 38:2; [M-H]-@6.51	ME215631	1.39	0.97	0.90	1.01	0.70	0.90
PE 35:4; [M-H]-@6.06	ME215545	1.36	1.19	1.01	1.06	0.64	0.63
PE 44:4; [M-H]-@8.58	ME215576	1.09	1.16	1.24	0.92	0.44	1.04
PE 38:1; [M-H]-@7.97	ME215555	1.19	1.08	1.04	0.91	0.60	1.06
PE 41:1; [M-H]-@8.69	ME215569	1.29	1.15	0.89	0.78	0.74	1.04
PG 34:1; [M-H]-@5.78	ME215582	1.22	1.06	0.94	0.88	0.74	1.06
PE 34:1; [M-H]-@6.84	ME215540	1.10	1.16	0.91	0.87	0.73	1.10
PE 37:4; [M-H]-@6.68	ME215553	1.18	1.11	0.86	0.83	0.75	1.15
PE 40:1; [M-H]-@8.46	ME215562	1.17	1.23	1.08	0.79	0.83	0.87
PS 36:1; [M-H]-@6.37	ME215626	1.10	1.06	1.14	0.85	0.84	1.00
PE 42:2; [M-H]-@8.46	ME215571	1.12	1.16	1.18	0.86	0.69	0.95
PG 36:2; [M-H]-@5.86	ME215586	1.06	1.07	1.18	0.98	0.65	1.00
PS 40:2; [M-H]-@7.01	ME215637	0.96	1.10	1.06	1.15	0.75	0.91
PS 38:1; [M-H]-@6.97	ME215630	1.11	0.99	0.85	1.09	0.97	0.93
PG 35:1; [M-H]-@6.06	ME215584	1.19	1.18	0.88	0.96	0.80	0.89
CL 74:5; [M-2H](2-)@6.07	ME215442	1.06	1.17	0.77	1.10	0.76	0.99
PE 38:2; [M-H]-@7.51	ME215556	1.17	1.12	0.87	1.10	0.66	0.93
CL 76:12; [M-2H](2-)@8.80	ME215449	1.29	1.41	0.49	1.07	0.63	0.81
PA 34:1; [M-H]-@5.67	ME215470	1.34	1.19	0.39	0.90	0.88	1.06
PE 34:3; [M-H]-@6.04	ME215542	0.79	1.39	0.65	1.13	0.73	1.10
CL 70:5; [M-2H](2-)@5.94	ME215435	0.73	1.22	0.57	1.18	0.77	1.31
CL 70:3; [M-2H](2-)@6.33	ME215433	0.86	1.18	0.66	1.08	0.72	1.29
PE 34:2; [M-H]-@6.40	ME215541	0.87	1.18	0.69	1.10	0.71	1.25
PE 39:6; [M-H]-@6.60	ME215561	1.05	1.00	0.73	0.84	0.62	1.54
PS 38:3; [M-H]-@6.16	ME215632	0.89	1.43	0.66	0.77	0.53	1.45
PE 40:8; [M-H]-@5.94	ME215568	0.96	1.36	0.41	0.94	0.54	1.45
CL 82:9; [M-2H](2-)@7.08	ME215454	0.97	1.43	0.48	0.80	0.63	1.38
PE 40:5; [M-H]-@7.10	ME215566	1.04	1.35	0.57	0.80	0.60	1.37
PE 35:2; [M-H]-@6.67	ME215544	0.89	1.51	1.08	0.92	0.59	0.90
PE 39:4; [M-H]-@7.16	ME215560	1.09	1.16	0.68	1.26	0.50	1.04
CL 76:11; [M-2H](2-)@9.01	ME215448	1.31	1.23	0.68	1.07	0.46	0.96
PE 36:3; [M-H]-@6.54	ME215548	1.25	1.18	0.74	1.05	0.43	1.08
CL 74:7; [M-2H](2-)@6.09	ME215444	0.99	1.57	0.75	0.81	0.41	1.19
PE 36:4; [M-H]-@6.22	ME215549	1.16	1.37	0.86	0.86	0.38	1.11
PE 38:5; [M-H]-@6.53	ME215557	1.25	1.42	0.69	0.75	0.51	1.12
PE 36:2; [M-H]-@6.97	ME215547	1.08	1.30	0.72	0.96	0.53	1.16
PE 40:7; [M-H]-@6.18	ME215567	0.96	1.39	0.65	1.07	0.58	1.10
PE 39:1; [M-H]-@8.20	ME215559	1.18	1.52	0.70	0.93	0.54	0.88
PS 39:4; [M-H]-@6.12	ME215635	1.04	1.40	0.83	0.94	0.65	0.96
CL 68:1; [M-2H](2-)@7.30	ME215431	0.38	1.21	1.08	0.64	0.86	1.81
PE 37:2; [M-H]-@7.24	ME215552	0.65	1.04	0.87	0.80	0.97	1.62
plasmenyl-PE 32:0; [M-H]-@7.09	ME215657	0.52	0.83	0.92	0.75	1.30	1.75
PC 40:6; [M-Ac-H]-@6.72	ME215523	0.52	1.47	0.72	0.70	1.03	1.47
plasmenyl-PE 38:6; [M-H]-@6.56	ME215670	0.57	1.41	0.62	0.61	1.21	1.53
PC 36:6; [M-Ac-H]-@5.40	ME215509	0.50	1.45	1.03	0.57	1.09	1.40
PC 38:6; [M-Ac-H]-@6.05	ME215517	0.50	1.53	0.81	0.62	1.27	1.31
PE 35:1; [M-H]-@7.14	ME215543	1.01	1.46	0.68	0.60	0.92	1.20
PS 38:5; [M-H]-@5.59	ME215634	0.94	1.61	0.56	0.63	0.82	1.24
PC 37:5; [M-Ac-H]-@6.07	ME215511	0.80	1.46	0.74	0.43	0.87	1.57
PE 37:5; [M-H]-@6.08	ME215554	0.77	1.31	0.80	0.58	0.87	1.55
PI 34:1; [M-H]-@5.65	ME215610	0.63	1.74	0.65	0.45	0.82	1.53
plasmenyl-PE 40:6; [M-H]-@7.18	ME215675	0.70	1.72	0.59	0.59	0.70	1.46
PS 35:1; [M-H]-@6.08	ME215625	0.85	1.64	0.67	0.58	0.68	1.36
PS 36:2; [M-H]-@5.90	ME215627	0.80	1.48	0.60	0.67	0.72	1.51
CL 72:8; [M-2H](2-)@8.91	ME215441	0.80	1.51	0.60	0.59	0.88	1.44
PI 32:1; [M-H]-@5.04	ME215609	0.77	1.61	0.63	0.62	0.85	1.36
PG 44:8; [M-H]-@5.62	ME215607	1.17	0.22	3.89	1.04	0.21	0.16
PG 38:4; [M-H]-@5.38	ME215591	0.70	0.35	3.63	0.76	0.98	0.46
PG 40:6; [M-H]-@5.38	ME215596	0.79	0.25	3.47	0.82	1.02	0.48
PG 44:9; [M-H]-@5.41	ME215608	1.09	0.43	3.23	0.83	0.58	0.45
PG 40:5; [M-H]-@5.62	ME215595	1.20	0.15	3.05	1.17	0.78	0.26
PG 42:8; [M-H]-@5.17	ME215602	1.05	0.08	3.37	1.22	0.70	0.27
PC 27:0; [M-Ac-H]-@4.92	ME215478	1.02	0.81	2.79	0.72	0.78	0.40
PG 38:5; [M-H]-@5.20	ME215592	1.02	0.26	2.86	1.10	0.95	0.42
PG 42:7; [M-H]-@5.51	ME215601	1.13	0.34	2.72	0.96	0.92	0.47
PG 44:10; [M-H]-@5.09	ME215604	1.08	0.38	2.76	0.94	0.91	0.48
lysoPE 22:1; [M-H]-@3.47	ME215651	0.15	0.14	3.11	0.26	3.58	0.33
lysoPE 22:2; [M-H]-@2.88	ME215652	0.19	0.17	3.51	0.36	2.77	0.43
lysoPE 18:1; [M-H]-@1.78	ME215645	0.28	0.29	2.88	0.34	2.84	0.61
lysoPE 20:2; [M-H]-@2.08	ME215647	0.35	0.20	3.00	0.42	2.82	0.49
PG 38:6; [M-H]-@4.70	ME215593	0.91	0.29	2.74	0.69	1.66	0.52
PG 42:9; [M-H]-@4.90	ME215603	0.78	0.16	2.72	0.60	2.10	0.58
FFA(22:3)	ME215465	0.72	0.17	2.54	1.20	1.81	0.35
FFA(24:3)	ME215469	0.46	0.20	2.60	1.02	2.27	0.41
lysoPE 16:1; [M-H]-@1.21	ME215643	0.21	0.48	2.41	0.55	2.39	0.89
FFA(22:2)	ME215464	0.51	0.22	2.27	0.99	2.43	0.48
FFA(20:2)	ME215461	0.49	0.27	1.97	0.97	2.52	0.61
FFA(24:2)	ME215468	0.50	0.29	2.04	0.81	2.53	0.70

Factors:

F1	AOM:NO \| Fish Oil:NO \| Normal:YES \| Sample type:Colon
F2	AOM:NO \| Fish Oil:YES \| Normal:YES \| Sample type:Colon
F3	AOM:YES \| Fish Oil:NO \| Normal:NO \| Sample type:Intestinal Neoplasms
F4	AOM:YES \| Fish Oil:NO \| Normal:YES \| Sample type:Colon
F5	AOM:YES \| Fish Oil:YES \| Normal:NO \| Sample type:Intestinal Neoplasms
F6	AOM:YES \| Fish Oil:YES \| Normal:YES \| Sample type:Colon

Data matrix